Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

Oncogenic KRAS is found in >25% of lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdow...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sunaga, Noriaki, Shames, David S., Girard, Luc, Peyton, Michael, Larsen, Jill E., Imai, Hisao, Soh, Junichi, Sato, Mitsuo, Yanagitani, Noriko, Kaira, Kyoichi, Xie, Yang, Gazdar, Adi F., Mori, Masatomo, Minna, John D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3061393/
https://ncbi.nlm.nih.gov/pubmed/21306997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0750
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares